Karlsberg Schaffer, S., Cubi-Molla, P., Devlin, N. and Towse, A.
This report details the views of a selection of experts in the fields of health and welfare economics on the cost-effectiveness threshold used by the National Institute for Health and Care Excellence (NICE) to decide which new medicines to recommend for use in the NHS, and the direction of future research in this area.
The objective of this OHE Consulting Report was to outline trends in Scottish Medicines Committee (SMC) advice decisions for medicines for the period October 2009 to September 2015. This report was initiated and funded by Pfizer Ltd. It specifically considers whether there were changes in the trends due to the adoption of new policies by the SMC, namely the increased use of modifiers when assessing cost-effectiveness (e.g.
Feng, Y., Devlin, N., Shah, K., Mulhern, B. and Van Hout, B.
This paper provides details of how the EQ-5D-5L value set was derived, focusing on the methods used to model the stated preference data. Results for different model specifications, and taking different interpretations of the data, are presented and discussed. This paper is intended to accompany OHE Research Paper 16/01: ‘Valuing Health-Related Quality of Life: An EQ-5D-5L Value Set for England’.
Devlin, N., Shah, K., Feng, Y., Mulhern, B. and Van Hout, B.
This paper reports the methods and findings from the EQ-5D-5L value set for England study. The value set is derived from the stated preference data of 996 members of the English general public. The study design followed the EuroQol Group’s international protocol for valuing EQ-5D-5L health states. A single value set is reported, and implications for public decisions made using EQ-5D-5L data are discussed. This paper is intended to accompany OHE Research Paper 16/02: ‘New Methods for Modelling EQ-5D-5L Value Sets: An Application to English Data’.
This paper presents a model to capture the behaviour of health sector decision makers when making resource allocation decisions on the level and mix of healthcare production, while taking into consideration the maximum expenditure (budget) allowed by the government or the health system regulator.
The paper seeks to address two perennial policy and practical discussions in the UK National Health Service (NHS) (and elsewhere): how to cope with financial austerity; and the opportunity costs of reimbursing new health technologies.
Cole, A., Garrison, L., Mestre-Ferrandiz, J. and Towse, A.
The objective of this OHE Consulting Report was to understand and develop a view on the core principles that should govern how Real-World Data (RWD) is accessed or generated, and used credibly to produce or generate Real-World Evidence (RWE), thereby working toward a set of “international standards”.
Mestre-Ferrandiz, J., Towse, A., Dellamano, R. and Pistollato, M.
Multi-indication pricing (MIP) involves setting a different price for each major indication approved for a medicine. As value is likely to differ across major indications, if prices paid for on-patent medicines are to reflect their value, then multi-indication medicines should have different prices across major indication, reflecting different values.